US needs to look differently at public health preparedness, says former FDA commissioner Gottlieb

Speaking at CPHI North America, Dr Scott Gottlieb shares insights into how the US should prepare for future pandemics by building out vaccine capacities
The ongoing coronavirus pandemic means the US will need to look at public health preparedness through the lens of national security and treat it on par with other kinds of national security threats, according to former US Food and Drug Administration Commissioner, Dr Scott Gottlieb on Tuesday.
Speaking at the hybrid CPHI North America event, Gottlieb said the pandemic had changed the course of history, reset the global order in many significant ways from a geopolitical standpoint, cost trillions of dollars and superseded all other national priorities for more than a year.
“We’re seeing the outsized impact that pathogens and pandemics can have and it means we have to reset how we look at these kinds of risks,” he told delegates.
Outlining the practical measures to tackle future healthcare crises, Gottlieb said the US needs to build different capacities.
“We clearly didn’t have the capacities we thought we had and that we certainty needed,” he said.
He said that the after US’ pandemic planning in 2003, which was focused on concern around H5N1 flu, the country invested in building out certain capacities such as cell-based manufacturing facilities for vaccines, as well as stockpiles and antivirals.
“What happened over time was those efforts atrophied and we didn’t continue to invest in keeping them ready,” he said. “We had this idea that we would create a warm base of preparedness when really what we needed was a hot base of preparedness. You can’t build a vaccine manufacturing plant and mothball it. You really need to be operating these things at scale; in part, because you need to be able to make continuing investments to keep facilities up to date and in part because the only way you can retain personnel to run these kinds of facilities and be ready to scale them up in the event of an emergency is to be operating them.”
He described the country’s prior focus on flu as a mistake: “Even after SARS and MERS came along and it was apparent that coronaviruses were on the march and represented a different kind of threat, we never pivoted our thinking; we never invested in broader capacities that looked beyond flu.”
To register for our four-week hybrid event, CPHI North America and to watch the full webinar on demand, click here.

Related News
-
News Merck invests US$1 billion in new USA-based vaccine facility
Merck annouces the opening of a new state-of-the-art vaccine production plant in Durham, North Carolina, USA, in efforts to bring pharmaceutical product development onto home soil in face of new import tariffs. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Trump's federal funding shift could stifle biotech innovation
Over a month into the second term of Donald Trump’s presidency and we have already seen some big changes affecting the healthcare industry. -
News Sanofi receives FDA warning over contamination at manufacturing site
The FDA issues a warning letter to Sanofi over contamination violations found at the Framingham biologics facility, in Boston, MA, USA.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance